Print Page | Sign In | Join
News & Press: Other

TherapeuticsMD ranks No. 1 among Florida companies in Deloitte Technology Fast 500

Saturday, December 20, 2014   (0 Comments)
Share |


TherapeuticsMD ranks No. 1 among Florida companies in Deloitte Technology Fast 500

BOCA RATON, Fla., November 20, 2014 – TherapeuticsMD Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced its ranking as Florida’s fastest-growing company by the recently released 2014 Deloitte Technology Fast 500.

With an overall ranking of 41 out of the 500 fastest-growing technology companies in North America, TherapeuticsMD is among eleven Florida companies included on the annual list.

“We are very pleased to be recognized as one of the top growth companies this year. It is an exciting time in our development, and we appreciate this acknowledgement by Deloitte,” said TherapeuticsMD CEO Robert G. Finizio.

In its 20th year, the Deloitte Technology Fast 500 is a yearly technology ranking of public and private companies in various industry sectors, including biotechnology/pharmaceutical, clean technology, computers, Internet, medical equipment, semiconductor and software.

About TherapeuticsMD Inc.
TherapeuticsMD Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its patented SYMBODA™ technology platform, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins and cosmetics under the vitaMedMD® and BocaGreenMD® brands. More information is available at the following websites:,, and

This press release by TherapeuticsMD Inc. may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company’s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website:

# # #

Dan Cartwright
Chief Financial Officer
Julia Amadio
Chief Product Officer

About BioFlorida

BioFlorida is the voice of Florida's life sciences industry, representing 6,200 establishments and research organizations in the BioPharma, MedTech and HealthIT that collectively employ 87,000 Floridians.

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.